Satomi A, Takada Y, Ishida K
Gan To Kagaku Ryoho. 1987 Jul;14(7):2262-8.
In order to examine the clinical usefulness of intralymphatic chemotherapy and the regimen of the appropriate anticancer drug for this route, we measured serum and tissue drug levels following intralymphatic administration of Futraful (FT) or Neocarzinostatin (NCS) in rabbits. The results were as follows: When a low-molecular-weight drug such as FT was administered into the lymphatic vessels, most of the drug flowed into the systemic circulation through the thoracic duct, but some leaked from the lymphatic vessels and flowed into the portal vein via the intestine. In the case of a high-molecular-weight drug such as NCS, there was a tendency for it to remain in the lymph nodes. It therefore seems that a drug of high molecular weight is most suitable for use in intralymphatic administration.
为了研究淋巴管内化疗的临床实用性以及适用于该给药途径的抗癌药物方案，我们在兔体内淋巴管内给予喃氟啶（FT）或新制癌菌素（NCS）后，测定了血清和组织中的药物水平。结果如下：当向淋巴管内注入低分子量药物如FT时，大部分药物通过胸导管流入体循环，但有一些药物从淋巴管漏出并经肠道流入门静脉。对于高分子量药物如NCS，其有在淋巴结中潴留的倾向。因此，高分子量药物似乎最适合用于淋巴管内给药。
